Lawrence Otto Klein - 10 Sep 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
CBO & COO
Signature
/s/ Michael Esposito, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
10 Sep 2021
Net transactions value
-$495,837
Form type
4
Filing time
14 Sep 2021, 21:44:27 UTC
Previous filing
27 May 2021
Next filing
01 Oct 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +10,000 +952% 11,050 10 Sep 2021 Direct F1, F2
transaction CRSP Common Shares Tax liability $495,837 -4,207 -38% $117.86 6,843 13 Sep 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Tax liability -10,000 -100% 0 10 Sep 2021 Common Shares 10,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.